Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Future-Trop2: TROP2 Precision Therapy in TNBC
NCT05928780Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of sacituzumab govitecan in triple negative breast cancer (TNBC), sponsored by Fudan University. Status: unknown.
02
Drugs
sacituzumab govitecan
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05928780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928780.